Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 30, 2023

First-Line Cemiplimab Monotherapy and Continued Cemiplimab Plus Chemotherapy Beyond Progression for Advanced NSCLC With PD-L1 Expression ≥50%

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
Lancet Oncol 2023 Aug 14;[EPub Ahead of Print], M Özgüroğlu, S Kilickap, A Sezer, M Gümüş, I Bondarenko, M Gogishvili, M Nechaeva, M Schenker, I Cicin, GF Ho, Y Kulyaba, K Zyuhal, RI Scheusan, MC Garassino, X He, M Kaul, E Okoye, Y Li, S Li, JF Pouliot, F Seebach, I Lowy, G Gullo, P Rietschel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading